Advertisement

Cancer Immunology, Immunotherapy

, Volume 18, Issue 3, pp 149–154 | Cite as

A randomized trial of chemoimmunotherapy of acute nonlymphocytic leukemia in adults using a protein-bound polysaccharide preparation

  • Ryozo Ohno
  • Kazumasa Yamada
  • Toru Masaoka
  • Toshiteru Ohshima
  • Ichita Amaki
  • Yutaka Hirota
  • Noboru Horikoshi
  • Atsushi Horiuchi
  • Kuniyuki Imai
  • Ikuro Kimura
  • Koichi Kitajima
  • Hiroyuki Nakamura
  • Toru Nakamura
  • Yoshiro Ohta
  • Yasunobu Sakai
  • Mineya Tanaka
  • Kazuo Tsubaki
  • Haruto Uchino
  • Nobuya Ogawa
  • Kiyoji Kimura
Original Articles

Summary

The effect of immunotherapy with a protein-bound polysaccharide preparation termed PSK on remission duration and survival of adults with acute nonlymphocytic leukemia (ANLL) was studied in a prospective randomized cooperative trial. After having achieved complete remission and receiving a consolidation therapy, 73 patients were randomized either to maintenance chemotherapy or to maintenance chemotherapy plus immunotherapy with PSK. Ultimately 36 patients in the chemotherapy group and 31 in the chemoimmunotherapy group were evaluable. Six months after the last entry, immunotherapy with PSK showed a borderline beneficial effect on remission duration (P=0.089) and on duration of survival (P=0.062). When the data were analyzed 12, 18, and 24 months after the last entry there were no significant differences in duration of remission and survival between the two groups. However, analysis of the data of patients who had maintained complete remission for more than 270 days revealed that immunotherapy had a suggestive beneficial effect (P=0.105), prolonging the 50% remission period by 418 days (885 vs 467 days). Thus, immunotherapy with PSK seems to be active in the treatment of adult ANLL when used for maintenance therapy in combination with chemotherapy, especially in patients with a good prognosis.

Keywords

Leukemia Beneficial Effect Polysaccharide Cancer Research Complete Remission 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Akiyama J, Kawamura T, Gotohda E, Yamada Y, Hosokawa M, Kodama T, Kobayashi H (1977) Immunochemotherapy of transplanted KMT-17 tumor in WKA rats by combination of cyclophosphamide and immunostimulatory protein-bound polysaccharide isolated from Basidiomycetes. Cancer Res 37:3042Google Scholar
  2. 2.
    Gale RP, Foom KA, Cline MJ (1981) Intensive chemotherapy for acute myelogenous leukemia. Ann Intern Med 94:753Google Scholar
  3. 3.
    Gutterman JU, Hersh EM, Rodriguez V, McCredie KB, Mavligit G, Reed R, Burgess MA, Smith T, Gehan EA, Bodey GPS, Freireich EJ (1974) Chemoimmunotherapy of adult acute leukemia. Prolongation of remission in myeloblastic leukemia with BCG. Lancet II:1405CrossRefGoogle Scholar
  4. 4.
    Hamilton-Fairly G (1976) Immunotherapy in the management of myelogenous leukemia. Arch Intern Med 136:1406Google Scholar
  5. 5.
    Hattori T, Niimoto M, Koh T, Nakano A, Oride M, Takiyama W, Nishimawari K (1979) Post-operative long-term adjuvant immunotherapy with mitomycin-C, PSK and FT-207 in gastric cancer patients. Jpn J Surgery 9:110Google Scholar
  6. 6.
    Kataoka T, Oh-hashi F, Tsukagoshi S, Sakurai Y (1977) Enhanced induction of immune resistance by concanavalin A-bound L1210 vaccine and an immunopotentiator prepared from Coriolus versicolor. Cancer Res 37:4416Google Scholar
  7. 7.
    Kato Y, Kawashima K, Ohno R, Yamada K (1983) Treatment of adult nonlymphocytic leukemia with BHAC-DMP therapy. Acta Haematol Jpn 46:1077Google Scholar
  8. 8.
    Kieting NJ, Smith TL, Gehan EA, McCredie KB, Bodey GP, Spitzer G, Hersh E, Gutterman J, Freireich EJ (1980) Factors related to length of complete remission in adult acute leukemia. Cancer 45:2017Google Scholar
  9. 9.
    Lindemalm CS, Killander A, Bjorkholm M, Engstedt L, Franzen S, Gahrton G, Gullbring B, Holm G, Hoglund S, Hornstern P, Jameson S, Killander D, Klein E, Lantz B, Lockner D, Lonngvist B, Mellstedt H, Palmblad J, Pauli C, Reizenstein P, Simonsson B, Skarberg K-O, Uden A-M, Vanky F, Wadman B (1978) Adjuvant immunotherapy in acute nonlymphocytic leukemia. Cancer Immunol Immunother 4:179Google Scholar
  10. 10.
    Mathé G, Amiel JL, Schwarzenberg L, Schneider M, Cattan A, Schlumberger JR, Hayat M, de Vassal F (1969) Active immunotherapy for acute leukemia. Lancet I:697Google Scholar
  11. 11.
    Nagao T, Komatsuda M, Watanabe K, Nozaki H, Yamauchi K, Arimori S (1980) Immunotherapy of acute leukemia and malignant lymphoma with PSK. Gan-to-Kagakuryoho 7:1483Google Scholar
  12. 12.
    Nomoto K, Yoshikumi C, Matsunaga K, Fujii T, Takeya K (1975) Restoration of antibody-forming capacity by PS-K in tumor-bearing mice. Gann 66:365Google Scholar
  13. 13.
    Oh-hashi F, Kataoka T, Tsukagoshi S (1978) Effect of combined use of anticancer drugs with a polysaccharide preparation, Krestin, on mouse leukemia P388. Gann 69:255Google Scholar
  14. 14.
    Ohno R, Imai K, Yokomaku S, Yamada K (1975) Antitumor effect of protein-bound polysaccharide preparation, PS-K, against 3-methylcholanthrene-induced fibrosarcoma in C57BL/6 mice. Gann 66:679Google Scholar
  15. 15.
    Ohno R, Yokomaku S, Wakayama K, Sugiura S, Imai K, Yamada K (1976) Effect of protein-bound polysaccharide preparation, PS-K, on the immune response of mice to sheep red blood cells. Gann 67:97Google Scholar
  16. 16.
    Ohno R, Ueda R, Imai K, Kato Y, Watanabe E, Morishima Y, Yokomaku S, Kobayashi M, Takeyma H, Ezaki K, Kawashima K, Hirano M, Ohara K, Kosaki T, Yoshikawa S, Yamada K (1978) A clinical trial of cell wall skeleton of BCG in chemoimmunotherapy of acute leukemia. Gann 69:179Google Scholar
  17. 17.
    Passe S, Mike V, Mertelsmann R, Gee TS, Clarkson BD (1982) Acute nonlymphocytic leukemia. Prognostic factors in adults. Cancer 50:1462Google Scholar
  18. 18.
    Peterson BA, Bloomfield CD, Bosl GJ, Gibbs G, Mallory M (1980) Intensive five-drug combination chemotherapy for adult acute nonlymphocytic leukemia. Cancer 46:663Google Scholar
  19. 19.
    Powles RL, Crowther D, Bateman CJT, Beard MEL, McElwain TJ, Russell J, Lister TA, Whitehouse JMA, Wrigley PFM, Pike M, Alexander P, Hamilton-Fairley G (1973) Immunotherapy for acute myelogenous leukaemia. Br J Cancer 34:1558Google Scholar
  20. 20.
    Rees JKH, Sandler RM, Challener J, Hayhoe FGJ (1977) Treatment of acute myeloid leukemia with triple cytoxic regime: DAT. Br J Cancer 36:770Google Scholar
  21. 21.
    Reizenstein P, Brenning G, Engstedt L, Franzen S, Gahrton G, Gullbring B, Holm G, Hocker P, Hoglund S, Hornsten P, Jameson S, Killander A, Killander D, Klein E, Lantz B, Lindmaim C, Lockner D, Lonqvust B, Mellstedt H, Palmblad J, Pauli C, Skarberg K-O, Uden A-M, Vanky F, Wadman B (1977) Effect of immunotherapy on survival and remission duration in acute nonlymphatic leukemia. In: Terry WD, Windhorst D (eds) Immunotherapy of cancer: Present status of trials in man. Raven Press, New York, p 329Google Scholar
  22. 22.
    Sakita M, Imai H, Kasuga M, Kageyama N, Imaki S, Tamai M, Fujita Y, Majima S (1983) Effect of a protein-bound polysaccharide preparation, PS-K, on dimethyl hydrazine induction of intestinal tumor in rats. Gann 74:351Google Scholar
  23. 23.
    Terry WD, Windhorst D (eds) (1978) Immunotherapy of cancer: Present status of trials in man. Raven Press, New York, p 307 (Progress in cancer research and therapy, vol. 6)Google Scholar
  24. 24.
    Tsukagoshi S, Oh-hashi F (1974) Protein-bound polysaccharide preparation, PS-K, effective against mouse sarcoma-180 and rat ascites hepatoma AH-13 by oral use. Gann 65:557Google Scholar
  25. 25.
    Tsuru S, Oka M, Hatsuse K, Iwasa I, Zinnaka Y, Nomoto K (1981) Effect of PSK against immunosuppressive factors in the serum of patients with gastric cancer. Igakunoayumi 119:932Google Scholar
  26. 26.
    Uzuka Y, Lion SK, Yamagata S (1979) Treatment of adult acute leukemia using intermittent combination chemotherapy with daunomycin, cytosine arabinoside, 6-mercaptopurine and prednisolone — DCMP two-step therapy. Tohoku J Exp Med 118 [Suppl]:212Google Scholar
  27. 27.
    Vogler WR, Chan YK (1974) Prolonging remission in myeloblastic leukemia by Tice-strain Bacillus Calmette-Guérin. Lancet II:128CrossRefGoogle Scholar
  28. 28.
    Whittaker JA, Bailey-Wood R, Hutchins S (1982) Active immunotherapy for the treatment of acute myelogenous leukemia: the use of intravenous BCG and comparison between BCG and irradiated leukemic blast cells. In: Terry WD, Rosenberg SA (eds) Immunotherapy of cancer. Ravan Press, New York, p 23Google Scholar

Copyright information

© Springer-Verlag 1984

Authors and Affiliations

  • Ryozo Ohno
    • 1
  • Kazumasa Yamada
    • 2
  • Toru Masaoka
    • 3
  • Toshiteru Ohshima
    • 4
  • Ichita Amaki
    • 4
  • Yutaka Hirota
    • 5
  • Noboru Horikoshi
    • 6
  • Atsushi Horiuchi
    • 7
  • Kuniyuki Imai
    • 8
  • Ikuro Kimura
    • 9
  • Koichi Kitajima
    • 9
  • Hiroyuki Nakamura
    • 3
  • Toru Nakamura
    • 10
  • Yoshiro Ohta
    • 11
  • Yasunobu Sakai
    • 8
  • Mineya Tanaka
    • 7
  • Kazuo Tsubaki
    • 7
  • Haruto Uchino
    • 12
  • Nobuya Ogawa
    • 13
  • Kiyoji Kimura
    • 5
  1. 1.First Department of MedicineNagoya University HospitalNagoyaJapan
  2. 2.Department of MedicineNagoya University Branch HospitalNagoyaJapan
  3. 3.Department of MedicineThe Center for Adult DiseasesOsakaJapan
  4. 4.Department of MedicineNihon University HospitalTokyoJapan
  5. 5.Department of MedicineNational Nagoya HospitalNagoyaJapan
  6. 6.Department of ChemotherapyCancer Chemotherapy CenterTokyoJapan
  7. 7.Department of MedicineKinki University HospitalOsakaJapan
  8. 8.Department of ChemotherapyKomagome HospitalTokyoJapan
  9. 9.Department of MedicineOkayama University HospitalOkayamaJapan
  10. 10.Department of MedicineFukui Medical School HospitalFukuiJapan
  11. 11.Department of MedicineEhime University HospitalEhimeJapan
  12. 12.Department of MedicineKyoto University HospitalKyotoJapan
  13. 13.Department of PharmacologyEhime University School of MedicineEhimeJapan

Personalised recommendations